6,560 Shares in Insulet Corporation $PODD Acquired by Goodman Advisory Group LLC

Goodman Advisory Group LLC acquired a new position in Insulet Corporation (NASDAQ:PODD) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 6,560 shares of the medical instruments supplier’s stock, valued at approximately $1,865,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Nordea Investment Management AB increased its holdings in shares of Insulet by 35.0% in the 4th quarter. Nordea Investment Management AB now owns 551,133 shares of the medical instruments supplier’s stock worth $157,128,000 after buying an additional 142,922 shares during the last quarter. ING Groep NV increased its holdings in shares of Insulet by 88.5% in the 3rd quarter. ING Groep NV now owns 17,300 shares of the medical instruments supplier’s stock worth $5,341,000 after buying an additional 8,123 shares during the last quarter. Jain Global LLC increased its holdings in shares of Insulet by 148.2% in the 3rd quarter. Jain Global LLC now owns 106,710 shares of the medical instruments supplier’s stock worth $32,945,000 after buying an additional 63,719 shares during the last quarter. Fisher Asset Management LLC increased its holdings in shares of Insulet by 38.1% in the 3rd quarter. Fisher Asset Management LLC now owns 46,273 shares of the medical instruments supplier’s stock worth $14,286,000 after buying an additional 12,754 shares during the last quarter. Finally, Mitsubishi UFJ Trust & Banking Corp increased its holdings in shares of Insulet by 26.5% in the 4th quarter. Mitsubishi UFJ Trust & Banking Corp now owns 43,921 shares of the medical instruments supplier’s stock worth $12,484,000 after buying an additional 9,206 shares during the last quarter.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on PODD. William Blair began coverage on shares of Insulet in a report on Wednesday, May 20th. They issued an “outperform” rating on the stock. Evercore decreased their price target on shares of Insulet from $240.00 to $200.00 in a report on Thursday, May 7th. Rothschild & Co Redburn reissued a “neutral” rating and issued a $220.00 price target (down from $380.00) on shares of Insulet in a report on Friday, April 24th. Weiss Ratings lowered shares of Insulet from a “hold (c)” rating to a “hold (c-)” rating in a report on Friday, May 15th. Finally, Piper Sandler reduced their target price on shares of Insulet from $360.00 to $210.00 in a report on Wednesday, May 6th. Twenty-one analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $250.00.

Insulet Price Performance

PODD stock opened at $150.71 on Thursday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.81 and a current ratio of 2.49. Insulet Corporation has a 52 week low of $140.63 and a 52 week high of $354.88. The firm’s fifty day moving average is $172.28 and its 200 day moving average is $234.54. The firm has a market cap of $10.44 billion, a P/E ratio of 35.05, a P/E/G ratio of 1.26 and a beta of 1.13.

Insulet (NASDAQ:PODD) last released its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, beating the consensus estimate of $1.19 by $0.23. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The company had revenue of $761.70 million for the quarter, compared to analyst estimates of $729.89 million. During the same quarter last year, the firm earned $1.02 EPS. The firm’s quarterly revenue was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. Research analysts predict that Insulet Corporation will post 6.46 earnings per share for the current year.

Insider Activity at Insulet

In other Insulet news, Director Timothy C. Stonesifer bought 2,790 shares of Insulet stock in a transaction that occurred on Wednesday, June 3rd. The shares were bought at an average price of $143.51 per share, with a total value of $400,392.90. Following the acquisition, the director owned 9,041 shares in the company, valued at approximately $1,297,473.91. This trade represents a 44.63% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.36% of the company’s stock.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.